Impact of Nutrition and Exercise on Glucose Metabolism, Inflammation, and Body Composition in Older Breast Cancer Survivors
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Breast Cancer Survivorship
- Sponsor
- Baltimore VA Medical Center
- Enrollment
- 14
- Locations
- 1
- Primary Endpoint
- muscle performance
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of the study is to examine the effects of resistance training on the reasons (mechanisms) underlying the development of fatigue, muscle weakness and wasting (sarcopenia), and impaired physical functioning (poor balance and walking) associated with breast cancer survivorship.
Detailed Description
Breast cancer is the most frequently diagnosed cancer in women, representing 26% of all female cancers. It is also the second leading cause of cancer related deaths in the US for women. Side effects of the cancer and treatment therapies may result in inactivity and inadequate intakes of various nutrients, including protein and vitamin D, associated with cardiovascular disease (CVD) and type 2 diabetes. High concentrations of systemic and local inflammation correlate well with CVD and diabetes risk. There is substantial evidence to support that incorporating physical activity and nutrition into one's lifestyle can reduce inflammation and, ultimately, the progression to CVD and diabetes. Understanding the role of exercise and diet management in the health of breast cancer survivors will allow us to translate these findings into therapy guidelines.
Investigators
Alice S. Ryan, PhD
Professor
Baltimore VA Medical Center
Eligibility Criteria
Inclusion Criteria
- •Histologic evidence of previous breast cancer
- •Three months post active cancer therapy (i.e. radiation/chemotherapy)
- •Non smoker (non smoking for at least 12 months: cigarettes, cigars, pipes)
- •45-80 years of age
- •Menopause over one year (absence of menses for 12 months or greater)
- •Sedentary lifestyle (structured physical activity \</= 2x per week)
- •BMI \>/=18 and \<50 kg/m2
Exclusion Criteria
- •Unstable lymphedema (no intensive therapy, no recorded 10% change in arm volume or circumference, no more than one lymphedema-related infection requiring antibiotics and no change in ADLs due to a lymphedema exacerbation for the past 3 months)
- •Plans for surgery (e.g., breast reconstruction) during the study period
- •Evidence of recurrent cancer or metastases
- •Symptomatic heart disease, CAD, CHF, or uncontrolled hypertension (SBP over 180 mm HG) unless medically stabilized
- •Abnormal renal function (BUN above 40 mg/dl, Cr above 1.3 mg/dl, CrCl\<60mg/dl)
- •Anemia HCT below 30 mg/dl, platelets below 100,000/cm3
- •History of seizures or taking anti-seizure or anti convulsion medication
- •Untreated dyslipidemia with National Cholesterol ATPIII 10 year cardiac risk score greater than 10% (www.nhlbi.nih.gov/guidelines/cholesterol/atp3upd04.htm)
- •Allergic to lidocaine
- •Abnormal liver function
Outcomes
Primary Outcomes
muscle performance
Time Frame: change in muscle area between baseline and 16 weeks
muscle strength
Secondary Outcomes
- glucose tolerance(change in glucose levels between baseline and 16 weeks)